The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
11:23
Superliga | Arnold Garita has been presented at the red and white. What number will he wear?
11:08
The Minister of Labor stated before the meeting at Cotroceni on the topic of salaries: No salary will decrease, and more than two-thirds of salaries will have increases.
11:04
The Bucharest Tribunal decides today whether Ciprian Ciucu will escape judicial control or not.
11:00
Dragos Pislaru, the interim Minister of Labor, accused the CSM of creating an unnecessary controversy regarding the salaries of leadership positions in the judiciary, the issue having already been resolved.
11:00
Formula 1: Red Bull has extended Max Verstappen's contract until 2030
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
